Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Dr. Gerds on the State of Treatment in MPNs

March 3rd 2020

Aaron Gerds, MD, assistant professor of medicine in the Hematology and Medical Oncology Department at the Cleveland Clinic Taussig Cancer Institute, discusses the state of treatment in myeloproliferative neoplasms (MPNs).

Dr. Schroeder on Treatment Options for GVHD

February 28th 2020

Mark A. Schroeder, MD, discusses therapies currently available and being investigated to treat patients with graft-versus-host disease.

Dr. Rossetti on Symptom Management for MPNs

February 27th 2020

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Dr. Pemmaraju on Methods to Treat Anemia in MPNs

February 27th 2020

Naveen Pemmaraju, MD, discusses methods to address anemia in patients with myelodysplastic syndromes.

Dr. Kremyanskaya on Unmet Needs in Myelofibrosis

February 27th 2020

Marina Kremyanskaya, MD, PhD, discusses unmet needs in myelofibrosis.

Dr. Snyder on Transplant Updates in Myelofibrosis

February 26th 2020

David S. Snyder, MD, discusses updates in treating patients with myelofibrosis who undergo transplant.

Dr. Kuykendall on the Approval of Fedratinib in Myelofibrosis

February 26th 2020

Andrew T. Kuykendall, MD, discusses the additionof fedratinib to the treatment paradigm in myelofibrosis.

Dr. Garcia on the Tolerability of Navitoclax/Ruxolitinib in Myelofibrosis

February 26th 2020

Jacqueline S. Garcia, MD, discusses the tolerability of the combination of navitoclax plus ruxolitinib in patients with myelofibrosis.

Dr. Gerds on Luspatercept to Treat Anemia in Myelofibrosis

February 25th 2020

Aaron Gerds, MD, discusses results of a phase II trial examining the safety and efficacy of luspatercept as a treatment for anemia in patients with myelofibrosis.

Dr. Mesa on the Safety Profiles of JAK Inhibitors in Myelofibrosis

February 25th 2020

Ruben Mesa, MD, discusses the adverse events of ruxolitinib and fedratinib in myelofibrosis.

Dr. Jain on Challenges With Allogeneic Transplant in Myelofibrosis

February 25th 2020

Tania Jain, MBBS, discusses the challenges with allogeneic transplant in patients with myelofibrosis.

Dr. Rossetti on Symptom Management for Patients With MPNs

February 22nd 2020

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Dr. Michaelis on Treating Patients With Myelofibrosis and Anemia

February 22nd 2020

Laura C. Michaelis, MD, discusses the treatment of patients with myelofibrosis and anemia.

Dr. Rampal on Investigational Agents in MPNs

February 22nd 2020

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

Dr. Kuykendall on Toxicity Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

February 21st 2020

Andrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.

Dr. Kremyanskaya on Responses With CPI-0610 in Patients With Myelofibrosis

February 21st 2020

Marina Kremyanskaya, MD, PhD, discusses responses with CPI-0610 in patients with myelofibrosis.

Dr. Garcia on the Role of Navitoclax in Myelofibrosis

February 21st 2020

Jacqueline S. Garcia, MD,discusses how navitoclax differs from other agents in primary or secondary myelofibrosis.

Expert Highlights Luspatercept Benefit as Treatment of Anemia in Myelofibrosis

February 21st 2020

Aaron Gerds, MD, discusses data presented at the 2019 ASH Annual Meeting highlighting luspatercept as a treatment of anemia in patients with myelofibrosis.

Panobinostat Combo Shows Early Promise in Myelofibrosis and Polycythemia Vera

February 21st 2020

The combination of panobinostat and ruxolitinib demonstrated efficacy and a tolerable safety profile as a treatment for patients with primary myelofibrosis and post-polycythemia vera–related myelofibrosis and post essential thrombocythemia–related myelofibrosis.

FDA Grants Priority Review to Cedazuridine/Decitabine for MDS and CMML

February 14th 2020

The FDA has granted a priority review designation to a new drug application for cedazuridine plus decitabine for the treatment of adult patients with previously untreated intermediate- and high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.